Welcome to Vertex Pharmaceuticals.
We believe that, just maybe, we can bring about a profound change in the treatment of serious diseases. This takes cutting-edge science and breakthrough therapies. We’ve built a worldwide community of top researchers and institutions that share our vision for change. With this approach, we think transformative solutions can be achieved even if there is never a “perfect cure.”
THE LIGHT
Strategy for success through collaboration, innovation and excellence
THE TUNNEL
The challenges are many
170 Million
estimated HCV-infected patients worldwide
More than
1,000
patients in PROVE trials
366,000
estimated HCV deaths per year, worldwide
2004
Vertex's telaprevir begins clinical development
2 million
undiagnosed HCV patients in US
39
patents filed or pending on novel HCV compounds
1989
Hepatitis C virus isolated and characterized
1994
Vertex began research targeting HCV protease
1 in 20
Americans carry abnormal CF gene
2006
Vertex began clinical development of VX-770
2,500
babies born with CF each year in the US
2008
Vertex conducting first
clinical trial of VX-809 in CF
37
average lifespan of CF patients
8
years of collaboration between
Vertex and CF Foundation
50,000
CF patients in US, Canada, Europe
2
fundamental novel CF mechanisms under investigation
by Vertex